Category - Developments

Developments

Precipio inks second development pact with H3 Biomedicine

Precipio (NASDAQ:PRPO) and closely-held H3 Biomedicine began a second development project to create a targeted gene panel that H3 will use in its ongoing clinical programs.

June 25, 2019

Developments

Dova Pharma gets European approval for thrombocytopenia drug

Dova Pharmaceuticals’ (NASDAQ:DOVA) DOPTELET has been granted European Commission (EC) marketing authorization for the treatment of severe thrombocytopenia in patients with chronic liver disease (CLD).

June 25, 2019

Developments

Zenabis outperforms design capacity by 35% in May; announces 70% increase in licensed annual cultivation capacity

Zenabis Global (TSX:ZENA) generated cultivation output in May of 908 kg of dried cannabis, which represents a 35.1% outperformance relative to design capacity.

June 24, 2019

Developments

Canopy Growth posts 191% jump in net revenue growth for fiscal 2019

Canopy Growth (TSX:WEED; NYSE:CGC) reported net revenue of $226.3-million for the fiscal year ended March 31, 2019, an increase of 191%, compared with $77.9-million a year earlier.

June 21, 2019

Developments

ContraVir Pharma gets positive FDA response to CRV431 pre-IND package for NASH

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that the FDA provided positive feedback to the company’s pre-IND meeting regarding CRV431 for the treatment of non-alcoholic steatohepatitis (NASH).

June 20, 2019

Developments

BeyondSpring set to join FTSE Russell 3000 Index

BeyondSpring (NASDAQ:BYSI) will join the FTSE Russell 3000 Index when markets open on July 1, according to a preliminary list of additions. Membership in the Russell 3000 Index, which remains in place for one year...

June 20, 2019

Developments

Akari reports positive initial results from Phase 1/2 atopic keratoconjunctivitis trial

Akari Therapeutics (NASDAQ:AKTX) reported positive data from the first part of its Phase 1/2 study of topical nomacopan in moderate to severe atopic keratoconjunctivitis (AKC).

June 19, 2019

Developments

Adamas Pharma reports new data from Phase 3 Parkinson’s disease trial

Adamas Pharmaceuticals (NASDAQ:ADMS) reported retrospective data from pooled Phase 3 trials of GOCOVRI in Parkinson’s disease (PD) patients.

June 19, 2019

Developments

FDA accepts Melinta Therapeutics sNDA for pneumonia drug

The FDA has accepted Melinta Therapeutics’ (NASDAQ:MLNT) supplemental NDA (sNDA) for BAXELDA for the treatment of community-acquired bacterial pneumonia (CABP).

June 19, 2019

Developments

Holders of Canopy Growth, Acreage Holdings approve proposed acquisition

Shareholders of Canopy Growth (TSX:WEED; NYSE:CGC) and Acreage Holdings (CSE:ACGR; OTC:ACRGF; FSE:0ZV) at separate meetings overwhelmingly approved the proposed acquisition of Acreage by Canopy through a share exchange.

June 19, 2019

Category - Developments

Precipio inks second development pact with H3 Biomedicine

Dova Pharma gets European approval for thrombocytopenia drug

Zenabis outperforms design capacity by 35% in May; announces 70% increase in licensed annual cultivation capacity

Canopy Growth posts 191% jump in net revenue growth for fiscal 2019

ContraVir Pharma gets positive FDA response to CRV431 pre-IND package for NASH

BeyondSpring set to join FTSE Russell 3000 Index

Akari reports positive initial results from Phase 1/2 atopic keratoconjunctivitis trial

Adamas Pharma reports new data from Phase 3 Parkinson’s disease trial

FDA accepts Melinta Therapeutics sNDA for pneumonia drug

Holders of Canopy Growth, Acreage Holdings approve proposed acquisition

General

More